#Sustainability #Sweden #Stockholm #Leqembi #BioArctic

BioArctic's 2025 Annual and Sustainability Reports Released

BioArctic AB, a pioneering biopharmaceutical company based in Sweden, has announced the publication of its Annual Report and Sustainability Report for the year 2025. The significant milestone for the company is now available on its official website, providing key insights into both financial performance and sustainability initiatives.

As stated by Gunilla Osswald, CEO of BioArctic, 2025 marked the onset of a new growth phase for the company. "We left behind two decades shaping our current identity, and I am proud to reflect on a year characterized by remarkable achievements, including the introduction of a groundbreaking Alzheimer’s drug to the global market," she remarked. This success reflects BioArctic's commitment to advancing innovative solutions in the field of neurodegenerative diseases.

The report illuminates BioArctic's pioneering contributions to Alzheimer’s treatment, particularly emphasizing the launch of Leqembi® (lecanemab), which stands as the world’s first drug demonstrated to slow cognitive decline in early Alzheimer’s patients. The collaboration with Eisai has been instrumental in navigating the drug's regulatory paths and global commercialization, marking a notable achievement for both companies.

In addition to the drug launch, BioArctic's growth in 2025 can be attributed to its robust pipeline of projects and various licensing agreements that contributed to record profits. This new chapter in the company’s history reflects a deep commitment to improving the lives of patients suffering from neurodegenerative disorders, supported by cutting-edge research including their proprietary BrainTransporter™ technology, which optimizes the delivery of treatment across the blood-brain barrier.

Furthermore, BioArctic is dedicated to maintaining transparency and fulfilling stakeholder requirements through its Sustainability Report. This document highlights the company's sustainable practices and innovation, aligning with the European Corporate Sustainability Reporting Directive and the European Sustainability Reporting Standards. By merging the Annual and Sustainability Reports, BioArctic seeks to provide a comprehensive overview of its operations, strategies, and governance measures.

BioArctic’s efforts in sustainability showcase its commitment to corporate accountability and ethical practices, aligning with modern expectations from investors and the public.

The Annual Report is readily accessible for download on BioArctic’s website, under the section for Investors/Financial reports and presentations, inviting stakeholders and interested parties to review the company's continued evolution and ambitious goals ahead.

This disclosure comes in compliance with the Swedish Securities Markets Act, showcasing BioArctic's transparency in public communication. The information was made available for public release on April 21, 2026, further reinforcing the company’s dedication to keeping its investors and stakeholders informed.

Investors and stakeholders seeking more information can contact Oskar Bosson, VP of Communications and Investor Relations, or Anders Martin-Löf, CFO, directly through the provided email addresses. BioArctic remains committed to innovating for a sustainable future and engaging with its community to enhance the quality of life for those impacted by neurodegenerative diseases.

To learn more about BioArctic and explore the full reports for 2025, visit www.bioarctic.com.